Skip to main content
AstraZenecaIn development

AstraZeneca profit jumps 23% as it unveils major savings plan

Source: Autobound Signal API · 80 signals tracked for AstraZeneca · updated

Get AstraZeneca's live signals in Claude or ChatGPT, or by API

AskWhat changed at AstraZeneca this week? Use Autobound signals for astrazeneca.com.

What happened

AstraZeneca is developing a weight-loss treatment to compete with Novo Nordisk and Eli Lilly.

Source

Article excerpt

AstraZeneca, Britain's biggest pharmaceutical company, said on Friday that its profit after tax rose 23% to $3.12 billion (€2.79bn) for the July to September period, driven largely by its cancer treatments. That marks a sharp pick-up from the rise of just over 2% in the previous quarter. The firm also launched a plan to generate $1.5 billion (€1.34bn) in annual savings, which it intends to reinvest mainly in the drugs it has in development. Revenue grew 7% to $16.2 billion (€14.5bn). Oncology, its biggest business, accounted for 48% of the total, with sales up 17% to $7.8 billion (€6.99bn), led by lung cancer drug Tagrisso and immunotherapy Imfinzi. Core earnings per share, which exclude items such as restructuring costs and the amortisation of acquired drugs, rose 17% to $2.79. The savings drive, called Reshaping for Sustainable Growth, will cost up to $2 billion (€1.79bn) in one-off restructuring charges and is due to be largely complete by the end of 2029. AstraZeneca said the savings would be reinvested in the company, principally in its pipeline of new drugs, as it plans to "redeploy resources" across its existing business to back more than 180 projects in development. Such restructuring could mean job cuts, though none have been announced. "With multiple potential blockbuster assets in late-stage development and transformative technologies scaling rapidly, we are on...

Keep reading with a free account

The rest of this article, and every signal for AstraZeneca, is in your free account.

Extracted from this sentence

It has reported 12 positive results from late-stage trials so far this year, and is also developing a weight-loss treatment to compete with drugs such as Novo Nordisk's Wegovy and Eli Lilly's Mounjaro.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
weight-loss treatment

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical

Extraction

Confidence
90%
Detected
Oct 30, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for AstraZeneca and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AstraZeneca this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/07dd0f64-400e-bbfb-0eef-0f59d6f6e0e1 returns this record as JSON. POST /v1/companies/enrich returns every signal for astrazeneca.com.

{
  "signal_id": "07dd0f64-400e-bbfb-0eef-0f59d6f6e0e1",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-30T12:17:41+00:00",
  "company": {
    "name": "AstraZeneca",
    "domain": "astrazeneca.com"
  },
  "data": {
    "url": "https://www.euronews.com/2026/10/30/astrazeneca-profit-jumps-23-on-cancer-drugs-as-it-unveils-major-savings-plan",
    "title": "AstraZeneca profit jumps 23% as it unveils major savings plan - Euronews.com",
    "excerpt": "AstraZeneca, Britain's biggest pharmaceutical company, said on Friday that its profit after tax rose 23% to $3.12 billion (€2.79bn) for the July to September period, driven largely by its cancer treatments. That marks a sharp pick-up from the rise of just over 2% in the previous quarter. The firm also launched a plan to generate $1.5 billion (€1.34bn) in annual savings, which it intends to reinvest mainly in the drugs it has in development. Revenue grew 7% to $16.2 billion (€14.5bn). Oncology, its biggest business, accounted for 48% of the total, with sales up 17% to $7.8 billion (€6.99bn), led by lung cancer drug Tagrisso and immunotherapy Imfinzi. Core earnings per share, which exclude items such as restructuring costs and the amortisation of acquired drugs, rose 17% to $2.79. The savings drive, called Reshaping for Sustainable Growth, will cost up to $2 billion (€1.79bn) in one-off restructuring charges and is due to be largely complete by the end of 2029. AstraZeneca said the savings would be reinvested in the company, principally in its pipeline of new drugs, as it plans to \"redeploy resources\" across its existing business to back more than 180 projects in development. Such restructuring could mean job cuts, though none have been announced. \"With multiple potential blockbuster assets in late-stage development and transformative technologies scaling rapidly, we are on...",
    "product": "weight-loss treatment",
    "summary": "AstraZeneca is developing a weight-loss treatment to compete with Novo Nordisk and Eli Lilly.",
    "planning": true,
    "image_url": "https://images.euronews.com/articles/stories/09/97/33/72/1200x675_cmsv2_2bfd85ad-6261-5cc7-a0bf-b4c254ff78f5-9973372.jpg",
    "confidence": 0.9,
    "product_data": {
      "name": "weight-loss treatment",
      "full_text": "a weight-loss treatment",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-10-30T12:17:41Z",
    "article_sentence": "It has reported 12 positive results from late-stage trials so far this year, and is also developing a weight-loss treatment to compete with drugs such as Novo Nordisk's Wegovy and Eli Lilly's Mounjaro."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.